JP2013544797A5 - - Google Patents

Download PDF

Info

Publication number
JP2013544797A5
JP2013544797A5 JP2013534982A JP2013534982A JP2013544797A5 JP 2013544797 A5 JP2013544797 A5 JP 2013544797A5 JP 2013534982 A JP2013534982 A JP 2013534982A JP 2013534982 A JP2013534982 A JP 2013534982A JP 2013544797 A5 JP2013544797 A5 JP 2013544797A5
Authority
JP
Japan
Prior art keywords
compound
salt
alkyl
group
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013534982A
Other languages
English (en)
Japanese (ja)
Other versions
JP5769326B2 (ja
JP2013544797A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/056505 external-priority patent/WO2012054367A1/en
Publication of JP2013544797A publication Critical patent/JP2013544797A/ja
Publication of JP2013544797A5 publication Critical patent/JP2013544797A5/ja
Application granted granted Critical
Publication of JP5769326B2 publication Critical patent/JP5769326B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013534982A 2010-10-19 2011-10-17 Rhoキナーゼ阻害薬 Active JP5769326B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39441410P 2010-10-19 2010-10-19
US61/394,414 2010-10-19
PCT/US2011/056505 WO2012054367A1 (en) 2010-10-19 2011-10-17 Rho kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2013544797A JP2013544797A (ja) 2013-12-19
JP2013544797A5 true JP2013544797A5 (enExample) 2014-12-04
JP5769326B2 JP5769326B2 (ja) 2015-08-26

Family

ID=44898209

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013534982A Active JP5769326B2 (ja) 2010-10-19 2011-10-17 Rhoキナーゼ阻害薬

Country Status (4)

Country Link
US (1) US9000154B2 (enExample)
EP (1) EP2630144B1 (enExample)
JP (1) JP5769326B2 (enExample)
WO (1) WO2012054367A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
EP2630144B1 (en) 2010-10-19 2016-09-07 Boehringer Ingelheim International GmbH Rho kinase inhibitors
US9499553B2 (en) 2013-03-13 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same
TW201506024A (zh) * 2013-07-02 2015-02-16 必治妥美雅史谷比公司 作為有效rock抑制劑的三環甲醯胺衍生物
JP6522602B2 (ja) * 2013-07-02 2019-05-29 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Rock阻害剤としての三環式ピリド−カルボキサミド誘導体
AR103990A1 (es) * 2015-01-09 2017-06-21 Bristol Myers Squibb Co Ureas cíclicas como inhibidoras de rock
JP6883173B2 (ja) 2015-05-12 2021-06-09 ヘモストッド エスエー 改善された血小板産生のための薬理学的特徴およびマイクロ流体特徴の組み合わせ
US12281308B2 (en) 2018-08-29 2025-04-22 University Of Massachusetts Inhibition of protein kinases to treat Friedreich ataxia

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210208A (en) 1990-09-24 1993-05-11 Rhone-Poulenc Rorer Pharmaceuticals Inc. Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
NZ240863A (en) 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
JPH11130751A (ja) 1997-10-30 1999-05-18 Yoshitomi Pharmaceut Ind Ltd アミド化合物およびそれらの酸付加塩の標識化合物
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
CZ2003182A3 (cs) * 2000-06-21 2003-06-18 F. Hoffmann-La Roche Ag Deriváty benzothiazolu
EP1339668A2 (en) 2000-11-28 2003-09-03 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and theirus
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
US7199147B2 (en) 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2003321472A (ja) * 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Grk阻害剤
WO2004071448A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
WO2004076420A1 (ja) * 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
WO2004101529A1 (ja) * 2003-05-19 2004-11-25 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
FR2862965B1 (fr) 2003-11-27 2007-09-07 Merck Sante Sas Nouveaux derives de phenoxyacetamides et leur utilisation pour la preparation de diphenylamides.
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
AU2005305140A1 (en) 2004-11-04 2006-05-18 Neurogen Corporation Arylalkyl ureas as CB1 antagonists
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
ES2580108T3 (es) 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
CA2664335C (en) 2006-09-20 2014-12-02 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
WO2008053319A1 (en) 2006-10-30 2008-05-08 Pfizer Products Inc. Amide resorcinol compounds
US8012955B2 (en) 2006-12-28 2011-09-06 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
CL2007003874A1 (es) 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
WO2008157330A1 (en) 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
US8445686B2 (en) 2007-08-27 2013-05-21 Abbvie Inc. 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
US20100227846A1 (en) 2007-08-30 2010-09-09 Takeda Pharmaceutical Company Limited Substituted pyrazole derivative
JP5544296B2 (ja) 2007-11-16 2014-07-09 ライジェル ファーマシューティカルズ, インコーポレイテッド 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
TW200944506A (en) 2008-03-26 2009-11-01 Takeda Pharmaceutical Substituted pyrazole derivatives and use thereof
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
EP2630144B1 (en) 2010-10-19 2016-09-07 Boehringer Ingelheim International GmbH Rho kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2013544797A5 (enExample)
JP2013530237A5 (enExample)
JP2018507877A5 (enExample)
JP2017509586A5 (enExample)
JP2016505010A5 (enExample)
JP2019518766A5 (enExample)
JP2016505042A5 (enExample)
JP2020502049A5 (enExample)
JP2010536761A5 (enExample)
JP2016510033A5 (enExample)
JP2012502890A5 (enExample)
JP5204091B2 (ja) 新規なベンジル(ヘテロサイクリックメチル)アミン構造を有するピリミジン化合物及びこれを含有する医薬
JP2009536620A5 (enExample)
JP2014139226A5 (enExample)
JP2010504908A5 (enExample)
JP2016518328A5 (enExample)
JP2017525737A5 (enExample)
JP2011505347A (ja) Dna中のg−四重鎖領域と相互作用するナフタレンジイミド化合物
JP2012515209A5 (enExample)
JP2019502763A5 (enExample)
JP2018522033A5 (enExample)
JP2018529770A5 (enExample)
JP2019531279A5 (enExample)
JP2015528488A5 (enExample)
JP2016529306A5 (enExample)